Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results and a corporate update.
Investors can access the live webcast and archived replay via the Investors section of the company website at www.kuraoncology.com.
Positive
- None.
Negative
- None.
News Market Reaction – KURA
In the Feb 26 session, KURA gained 1.05%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Investor conferences | Neutral | +2.1% | Participation in three March 2026 healthcare investor conferences. |
| Feb 6 | Inducement stock options | Neutral | +5.8% | Inducement grants totaling 69,750 options to new employees. |
| Jan 11 | Commercial update | Positive | -2.5% | FDA approval, KOMZIFTI launch and preliminary revenue and cash update. |
| Jan 5 | Inducement stock options | Neutral | -7.7% | Option grants to new employees under 2023 Inducement Option Plan. |
| Dec 8 | Clinical data update | Positive | -2.6% | Strong KOMZIFTI combo data in NPM1-mutated and KMT2A-rearranged AML. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: positive fundamental updates (FDA approval, strong combo data) on Dec 8, 2025 and Jan 11, 2026 saw negative moves, while routine items like inducement grants on Feb 6, 2026 produced a positive reaction. Conference participation on Feb 25, 2026 coincided with a modest gain.
Over the last few months, Kura Oncology has reported several notable milestones. On Dec 8, 2025, it released encouraging combination data for KOMZIFTI in AML. On Jan 11, 2026, it highlighted recent accomplishments, including FDA approval and commercial launch of KOMZIFTI and disclosed detailed revenue and cash figures, yet the stock fell 2.55%. Subsequent inducement grant updates on Jan 5 and Feb 6, 2026 and conference participation news on Feb 25, 2026 drew varied price reactions, suggesting no consistent pattern around routine corporate updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
